SecBot SecBot
6-K ·Filed Oct 26, 2026

RADX

Radiopharm Theranostics Ltd
NEUTRAL
Impact 4/10
Processed1h 8m ago SEC0001213900-26-112283
Notable filing: 6-K

Price Chart

Loading chart...

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001213900-26-112283
Document: ea030961801ex99-1.htm0001213900-26-112283
Document: 0001213900-26-112283-index-headers.html0001213900-26-112283
Document: 0001213900-26-112283-index.html0001213900-26-112283
Document: 0001213900-26-112283.txt0001213900-26-112283
32 reports for RADX
Performance horizon
69% Hit rate @ T+5 11 of 16 directional calls Went positive at some point 11 of 16 best @ T+60▲ +73.69%Jul 27, 2026
Filters
Rows
Reports for RADX — sortable, filterable
TypeNow
Oct 26, 2026
today
6-K
NEUTRAL ★ 4/10
—awaiting T+5——
Oct 20, 2026
6d ago
6-K
NEUTRAL ★ 3/10
$0.9900awaiting T+5—$1.01 (+2.02%)
Oct 14, 2026
11d ago
SC 13G
NEUTRAL ★ 3/10
$1.08 $0.9500▼ −12.04%▼ −11.02%$1.01 (−6.48%)
Oct 5, 2026
21d ago
6-K
BULLISH ★ 6/10
$1.27 $1.11▼ −12.60%▼ −13.02%$1.01 (−20.47%)
Oct 1, 2026
25d ago
6-K
NEUTRAL ★ 2/10
$1.48 $1.11▼ −25.00%▼ −26.30%$1.01 (−31.76%)
Sep 30, 2026
26d ago
6-K
NEUTRAL ★ 2/10
$1.62 $1.15▼ −29.01%▼ −30.93%$1.01 (−37.65%)
Sep 24, 2026
4w ago
EFFECT
BEARISH ★ 5/10
$1.57 $1.48▲ +5.85%▲ +5.43%$1.01 (+35.75%)
Sep 22, 2026
4w ago
6-K
NEUTRAL ★ 3/10
$1.65 $1.52▼ −7.88%▼ −6.69%$1.01 (−38.79%)
Sep 14, 2026
6w ago
6-K
BULLISH ★ 7/10
$2.01 $1.61▼ −19.90%▼ −20.01%$1.01 (−49.75%)
Sep 11, 2026
6w ago
6-K
NEUTRAL ★ 4/10
$1.98 $1.65▼ −16.67%▼ −16.45%$1.01 (−48.99%)
Showing 10 of 32

US Market Status

Market Closed — Opens in 20m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 26, 2026

Fresh RADX Intelligence

Analysis is for subscribers only.

Radiopharm Theranostics announced it received $8 million from Rockford Capital under a funding facility secured against its anticipated FY26 Australian R&D Tax Incentive (RDTI). The funds will support clinical trial pipeline and general working capital, with repayment due by October 2027.

Subscribe for Full Access